1. Диагностика и лечение артериальной гипертензии. Российские рекомендации. Кардиоваск. тер. и проф. Прил. 2. 2008; 7 (6).
2. Van der Lee R, Pfaffendorf M, ran Zwieten PA. The differential time course of the vasodilator effects of various 1,4-dihydropyridines in isolated human small arteries are correlated to their lipophilicity. J Hypertens 2000; 18: 1677–82.
3. Ahernethy DR, Schwartz JB. Calcium-antagonist drugs. N Engl J Med 1999; 341: 1447–57.
4. Herbette LG, Vecchiarelli M, Sartani A et al. Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties. Blood Press 1998; 7 (Suppl. 2): 10–7.
5. Gasser R, Koppel H, Klein W. Lercanidipine, a new third generation Ca-antagonist in the treatment of hypertension. J Clin Basic Cardiol 1999; 2: 169–74.
6. Epstein M. Calcium antagonists in the management of hypertension. In: Epstein M (ed). Calcium Antagonists in Clinical Medicine. 2nd ed. Philadelphia: Hanley & Belfus; 1998; 155–76.
7. Halperin AK, Icenogle MV, Kapsner CO et al. A comparison of the effects of nifedipine and verapamil on exercise performance in patients with mild to moderate hypertension. Am J Hypertens 1993; 6: 1025–32.
8. Zannad F, Boivin JM. Lorraine General Physician Investigators Group. Ambulatory 24-h blood pressure assessment of the felodipine-metoprolol combination versus amlodipine in mild to moderate hypertension. J Hypertens 1999; 17: 1023–32.
9. A 12-month comparison of ACE inhibitor and CA antagonist therapy in mild to moderate essential hypertension – The GLANT Study. Study Group on Long-term Antihypertensive Therapy. Hypertens Res 1995; 18 (3): 235–44.
10. Borhani N, Mercuri M, Borhani P et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA 1996; 276 (10): 785–91.
11. Hansson L. How to study the role of hypertension in atherosclerosis. Lessons from MIDAS. Multicentre Isradipine Diuretic Atherosclerosis Study. Blood Press 1996; Suppl. 4: 16–29.
12. Estacio RO, Schrier RW. Antihypertensive therapy in type 2 diabetes: implications of the appropriate blood pressure control in diabetes (ABCD) trial. Am J Cardiol 1998; 82 (9B): 9–14.
13. Schrier RW, Estacio RO, Jeffers B. Appropriate Blood Pressure Control in NIDDM (ABCD) Trial. Diabetologia 1996; 39 (12): 1646–54.
14. Tatti P, Pahor M, Byington RP et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21 (10): 1779–80.
15. Stason WB, Schmid CH, Niedzwiecki D et al. Safety of nifedipine in patients with hypertension. A meta-analysis. Hypertension 1997; 30: 7–14.
16. Alderman M, Cohen H, Roque R, Madhavan S. Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients. Lancet 1997; 349: 594–8.
17. Jick H, Derby L, Gurewich V, Vasilakis C. The risk of myocardial infarction associated with antihypertensive drug treatment in persons with uncomplicated essential hypertension. Pharmacotherapy 1996; 16: 321–6.
18. de Champlain J, Karas M, Nguyen P et al. Different effects of nifedipine and amlodipine on circulating catecholamine levels in essential hypertensive patients. J Hypertens 1998; 16 (11): 1357–69.
19. Brown MJ, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366–72.
20. Simon A, Gariepy J, Moyse D et al. Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes. Circulation 2001; 103: 2949–54.
21. Montro M, Shemesh J. Calcium channel blocker nifedipine slows down progression of coronary calcification in hypertensive patients compared with diuretics. Hypertension 2001; 37: 1410–3.
22. Fox KM, Mulkahy D, Findlay I, Dargie HJ on behalf of the TIBET Study Group. Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischemic burden in 608 patients with stable angina. Eur Heart J 1996; 17: 96–103.
23. Lubsen J, Pool-Wilson PA, Pocock SJ et al. Design and current status of ACTION: A Coronary disease Trial Investigating Outcome with Nifedipine GITS. Eur Heart J 1998; 19 (suppl. 1): 20–32.
24. Lubsen J, Wagener G, Kirwan BA et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stale angina and hypertension: the ACTION trial. J Hypertens 2005; 23 (3): 641–8.